Hassan Ramadan
Livonia, MINPI 1578200150
Payments from drug & device makers
Across 156 payments — averaging $20.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$728
- GSK$602
- Regeneron Healthcare Solutions, Inc.$419
- Sanofi$278
- CSL Behring$264
- Novartis$159
- plus $737 from 15 others
What the payments were for
- Food & beverage$3,05596%
- Education$1324%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 30 | $728 |
| GSK | 48 | $602 |
| Regeneron Healthcare Solutions, Inc. | 15 | $419 |
| Sanofi | 13 | $278 |
| CSL Behring | 11 | $264 |
| Novartis | 8 | $159 |
| Blueprint Medicines Corporation | 5 | $114 |
| Pfizer | 1 | $101 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $85 |
| Amgen | 3 | $70 |
| Organon | 4 | $69 |
| Pharming Healthcare, Inc. | 3 | $63 |
| Grifols USA, LLC | 2 | $51 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $48 |
| Optinose US, Inc. | 1 | $29 |
| Kaleo, Inc. | 1 | $26 |
| Lilly USA, LLC | 1 | $19 |
| LEO Pharma Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $15 |
| Dermavant Sciences, Inc. | 1 | $15 |
| Galderma Laboratories, L.p. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $33,111 |
| Spiriva RespimatTiotropium Bromide | 19 | $13,329 |
| Breo ElliptaFluticasone/Vilanterol | 33 | $13,066 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 38 | $5,244 |
| Azelastine Hcl | 143 | $4,040 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $2,867 |
| Montelukast Sodium | 172 | $1,751 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 13 | $1,705 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 50 | $1,586 |
| Ipratropium Bromide | 31 | $1,376 |
| Fluticasone Propionate | 95 | $1,256 |
| Ventolin HfaAlbuterol Sulfate | 12 | $655 |
| Levocetirizine Dihydrochloride | 17 | $274 |
| Famotidine | 24 | $261 |
| Ammonium Lactate | 12 | $167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $602 | $46,17772 claims |
| AstraZenecaSymbicort | $728 | $2,86713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Michiganon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.